Introduction
Acute kidney injury (AKI) is a multifactorial disease. It commonly complicates high-risk surgeries and appears as a consequence of systemic illness or injury [1] . More than 50% of intensive care unit (ICU) patients develop AKI (defined by Kidney Disease: Improving Global Outcomes [KDIGO] criteria), with ≥30% of these patients reaching the more severe KDIGO stages (stage 2 and 3) [2, 3] . Multiple studies have identified AKI as an important risk factor for high morbidity and mortality. Furthermore, it significantly increases the need for renal replacement therapy (RRT), hospital costs, and leads to end-stage renal disease (ESRD) or chronic kidney disease (CKD) [4, 5] . Despite increasing attention in recent years, little improvement in outcomes of AKI has occurred. There are two major challenges, the difficulty to detect AKI early and the poor understanding of its pathogenesis, have hampered the progress in AKI research and clinical management [1] . Current definitions of AKI including the risk, injury, failure, loss of function, ESRD, the Acute Kidney Injury Network, and the KDIGO criteria all rely on changes in either the levels of serum creatinine (sCr) and/or urinary output [6] [7] [8] [9] . sCr and oliguria are neither sensitive nor specific. Because both of them are markers of kidney function not of kidney injury or stress, and are easily influenced by many factors (including sex, muscle mass, medications or volume status), so using them may delay the diagnosis of AKI [1, 10] . Over the past decade, there have been numerous studies dedicated to discovering novel makers for an early detection of AKI in order to reverse the adverse outcomes of AKI. These biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), liver-type fatty acid binding protein (L-FABP), kidney injury molecule-1 (KIM-1), tissue inhibitor of metalloproteinases-2 (TIMP-2), and insulin-like growth factor-binding protein 7 (IGFBP7) [11] [12] [13] [14] . Among all these markers, [TIMP-2] · [IGFBP7] shows the best accuracy and stability, even in patients with chronic conditions such as diabetes mellitus, congestive heart failure and CKD [15] . In 2014, the Food and Drug Administration (FDA) approved the test "NephroCheck /1000) to be used in ICU patients to predict the risk of developing moderate to severe AKI within the prior 24 h [16] . Since then, more and more studies focused on the evaluation of the clinical application of NephroCheck ® . In this review, we summarize the current research status of cell cycle arrest biomarkers (TIMP-2 and IGFBP7), and discuss the advantages and limitations of using these biomarkers.
Biological characteristics
TIMP-2 has a molecular weight of approximately 24 kDa and IGFBP7 has a molecular mass of 29 kDa [17] . Both of them are expressed and secreted by renal tubular cells, and involved in G1 cell cycle arrest during the early phases of cellular stress or injury caused by various insults (e.g. sepsis, ischemia, oxidative stress and toxins) [18] .
In addition to the quiescent state (G0), the cell cycle includes four tightly controlled phases: G1, S (DNA synthesis), G2, and M (mitosis) [19] . Each phase of the cell cycle has a specific function for appropriate cell proliferation. Cells must enter and exit each phase of the cell cycle on schedule in order to divide and repair. This process is controlled by cyclins, cyclin-dependent kinases (CDK), and cyclin-dependent kinases inhibitors. If the cells stay in a phase too long or exit a phase too soon, the normal division and repair process can become maladaptive [20] . For instance, if the cells remain arrested in G1 or G2 phase instead of re-initiating the cell cycle, a senescent, hypertrophic and fibrotic cell phenotype will present. Conversely, exiting from the cell cycle in late G1 phase may lead to cell apoptosis [21] .
When exposed to cellular stress or injury, renal tubular cells may produce and release TIMP-2 and IGFBP7. TIMP-2 stimulates p27 expression and IGFBP7 directly increases the expression of p53 and p21. Then these p proteins block the effect of cyclin-dependent protein kinase complexes (CyclD-CDK4 and CyclE-CDK2) on cell cycle promotion, resulting in transient G1 cell cycle arrest, thereby providing cells an opportunity to repair DNA damage and regain function. This process happens during early cellular stress and may help cells maintain energy balance, prevent further DNA damage and division [22, 23] . But sustained cell cycle arrest will result in a senescent cell phenotype and lead to fibrosis. So cell cycle arrest is not only associated with increased risk for AKI but may also serve as a mechanistic link between AKI and CKD [19, 24] (Figure 1 ).
Clinical research
Before clinical application of NephroCheck ® , there have been three main studies for detecting and validating the ability of [TIMP-2] · [IGFBP7] to pre-diagnose AKI. These studies are summarized below and in Table 1 .
The Sapphire study was a multicenter observational study in heterogeneous critically-ill patients, which had two phases: discovery phase and validation phase. The primary endpoint was moderate-severe AKI (KDIGO stage 2-3) within 12 h of sample collection. The purpose of the discovery phase study was to identify novel potential biomarkers for AKI. In this phase, 522 adult ICU patients were enrolled and 340 biomarkers in the urine and blood were tested (including NGAL, KIM-1, IL-18, L-FABP). As shown by the results, TIMP-2 and IGFBP7 had the best performance, with an area under the receiver operating characteristic curve (AUC) of 0.80 for [TIMP-2] · [IGFBP7] (0.79 and 0.76, respectively), which was significantly superior to all previously described markers of AKI (p < 0.002) [23] . Subsequently, the outcome was validated in the validation phase study which included a heterogeneous sample of 728 critically-ill patients. The combined urine biomarker product of [TIMP-2] · [IGFBP7] was proved to be stable across clinical syndromes and significantly improved risk stratification [1] .
The Opal study was a derivation and validation study to confirm the accuracy and clinical utility of two high sensitivity/high negative predictive value (NPV) and 2.0 (ng/mL) 2 /1000 for high specificity/high positive predictive value (PPV). The results of the Opal study replicated those of the Sapphire study where the sensitivity at the 0.3 cutoff was 89%, and NPV was 97%. For 2.0 cutoff, specificity was 95% and PPV was 49% [25] .
The Topaz study enrolled 420 heterogeneous critically-ill patients in order to prospectively validate the lower (0.3) cutoff value for risk assessment of AKI. In this study, the endpoint was determined independently by clinical adjudication by three nephrologists who were blinded to the results of the test. [ 
Research of [TIMP-2] · [IGFBP7] in AKI associated with different etiologies
AKI is a multi-etiological disease, many studies have tried to clarify the practicality of urinary [TIMP-2] · [IGFBP7] in AKI of different etiologies. The major and recent studies in this regard are listed in Table 2 .
Cardiac surgery
Patients undergoing cardiac surgery are at high risk for AKI. A recent meta-analysis estimated the global incidence of AKI following cardiac surgery in adults to be approximately 22% [49] 
Major surgery
AKI also commonly complicates high-risk non-cardiac surgery which has received much less attention than cardiac surgery [50] . As demonstrated in Gocze et ADHF, acute decompensated heart failure; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; AUC, area under the receiver operating characteristic curve; CABG, coronary artery bypass surgery; CPB, cardiopulmonary bypass; DGF, delayed graft function; ICU, intensive care unit; KDIGO, Kidney Disease: Improving Global Outcomes; KT, kidney transplantation; NR, not report; OHCA, out-of-hospital cardiac arrest; TAVI, transcatheter aortic valve implantation; TIMP-2, tissue inhibitor of metalloproteinases-2; IGFBP7, insulin-like growth factor-binding protein 7. Table 2 (continued) to confirm which biomarker has better clinical utility of predicting AKI.
Sepsis
Sepsis is a major cause for AKI. In fact, almost half of AKI is caused by sepsis [51, 52] 2 /1000 ruled out the need for RRT [46] . This study showed that [TIMP-2] · [IGFBP7] is associated with AKI, but is not specific for sepsis. , sensitivity was 50%, specificity was 87%, NPV was 95% and PPV was 25% for the prediction of AKI within 72 h. So they concluded that urinary [TIMP-2] · [IGFBP7] measured after PBC may be a useful tool for early identification of patients at risk of developing platinum-induced AKI [47] . In contrast, in Toprak et al.'s study, those findings were not replicated [48] . Overall, these two studies had small sample size. Larger studies are required to determine whether [TIMP-2] · [IGFBP7] can predict cisplatin-related AKI. Recognizing the major risks associated with AKI and in an attempt to potentially reverse its adverse outcomes, the FDA has taken an important step to provide us with a new tool as an early alert of which patients are at imminent risk [58] . However, because AKI is often multifactorial, it seems unlikely that a single AKI biomarker would achieve troponin-like diagnostic accuracy. So like all diagnostic tests, NephroCheck ® is not a standalone test, it needs to be combined with clinical judgment (such as urine sediment score) in order to detect AKI with higher sensitivity and specificity [59] . Therefore, in future studies, how to combine NephroCheck ® test with other clinical examinations or symptoms to improve diagnostic accuracy is an important research direction.
Toxic renal disease

Future directions
TIMP-2 and IGFBP7 do not appear to persist in the urine for long after AKI, meanwhile, the combination of them is more sensitive to transient AKI with a higher delta NephroCheck ® score comparing to persistent AKI [60] . [61] . Therefore, NephroCheck ® may be normal in patients who have already manifested AKI by functional criteria (e.g. sCr). AKI complicating critical illness is highly heterogeneous in severity, etiology and timing, so defining the appropriate timing and frequency of biomarker measurement and interpreting these results in individual patients is extremely difficult [62] . However, it is very meaningful to verify the best time and frequency of NephroCheck ® test, for example, it can save unnecessary testing costs.
Some researchers suggest that [TIMP-2] · [IGFBP7] for the prediction of AKI might be most applicable in patients at high risk of AKI, and less precise in those at lower risk [63] . Among patients with AKI risk, applying high-sensitivity threshold could focus patient care on strategies of intensified monitoring prior to any increase in sCr. Furthermore, combining AKI diagnostic criteria (such as KDIGO criteria) with NephroCheck ® test results may enable us to predict the development trend of AKI, recovery or progress to the next phase of AKI. In this way, NephroCheck ® could be utilized and integrated with additional clinical information to help inform more complex and invasive management decisions, such as prediction of the need for RRT, and deciding when to start or stop RRT [64] . Meanwhile, the cost benefit of [TIMP-2] · [IGFBP7] test is unknown. We need more clinical trials and data to support the hypothesis that early recognition of kidney injury with [TIMP-2] · [IGFBP7] will prevent the progression of AKI or be associated with a cost benefit to the patient or institution, avoiding unnecessary and expensive diagnostic and therapeutic evaluations.
Furthermore, measurement of [TIMP-2] · [IGFBP7] not only provides information for predicting and diagnosing AKI, but also has the potential to help to identify patients who are at the highest risk of developing adverse outcomes [65] [66] [67] . Further studies to evaluate the predictive value of [TIMP-2] · [IGFBP7] for ICU stay, mortality and progression to ESRD, are needed. Moreover, the current studies looking into the mechanism by which the test works is still in the hypothesis phase, additional studies using conditional knockouts and pharmacologic inhibitors of TIMP-2 and IGFBP7 are needed to better define its mechanistic role in renal injury [68] . As a result, cell cycle regulation may become a potential new target for the prevention and treatment of AKI. We may even be able to prevent CKD progression by regulating cell cycle arrest [69] .
Conclusions
As a novel biomarker for predicting AKI, [ 
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